{
    "pmcid": "9792944",
    "qa_pairs": {
        "How many nanobodies were identified in the study with broad neutralizing activity against SARS-CoV-1, SARS-CoV-2 variants, and other sarbecoviruses?": [
            "593 nanobodies",
            "450 nanobodies",
            "700 nanobodies",
            "350 nanobodies"
        ],
        "What is the mechanism by which nanobody 3-2A2-4 prevents viral entry?": [
            "It interferes with the structural transition of the RBD from the 'down' to 'up' conformation.",
            "It directly blocks the ACE2 receptor on host cells.",
            "It degrades the spike protein through proteolytic activity.",
            "It binds to the viral RNA, preventing replication."
        ],
        "What is the primary target of the nanobodies developed in the study for neutralizing SARS-CoV-2 variants?": [
            "The SARS-CoV-2 spike protein",
            "The SARS-CoV-2 nucleocapsid protein",
            "The SARS-CoV-2 membrane protein",
            "The SARS-CoV-2 envelope protein"
        ],
        "What was demonstrated by in vivo studies regarding the efficacy of nanobody 3-2A2-4?": [
            "It protected mice from infection with authentic SARS-CoV-2 Delta and Omicron variants.",
            "It failed to protect mice from infection with SARS-CoV-2 Delta and Omicron variants.",
            "It only protected mice from infection with SARS-CoV-2 Delta variant.",
            "It only protected mice from infection with SARS-CoV-2 Omicron variant."
        ],
        "Which specific nanobody was highlighted for its ability to bind a highly conserved epitope on the RBD?": [
            "Nanobody 3-2A2-4",
            "Nanobody 5-1B1-3",
            "Nanobody 7-4C4-2",
            "Nanobody 2-3D3-1"
        ]
    }
}